Dihydroartemisinin

DRUG7 trials

Sponsors

Shanghai Zhongshan Hospital, Syamsudin Abdillah,Ph.D, Pharm D, The First Affiliated Hospital with Nanjing Medical University

Conditions

Acne VulgarisInfectionsMAFLDMalariaMalaria, VivaxMalaria,FalciparumPolycystic Ovary SyndromePolycystic Ovary Syndrome (PCOS)

Early Phase 1

Efficacy of Dihydroartemisinin for Treating Acne Vulgaris

RecruitingNCT07007078

Shanghai Zhongshan HospitalAcne Vulgaris

Start: 2025-06-30End: 2026-12-31Target: 60Updated: 2025-06-05

Phase 1

Dihydroartemisinin for MAFLD

RecruitingNCT07679542

The First Affiliated Hospital with Nanjing Medical UniversityMAFLD

Start: 2026-03-30End: 2026-09-01Target: 30Updated: 2026-07-01

Phase 2

Momordica Charantia and Dihydroartemisinin-piperaquined-primaquine for Uncomplicated Plasmodium Falciparum Malaria Patients in Southwest Sumba Regency

CompletedNCT05829187

Syamsudin Abdillah,Ph.D, Pharm DUncomplicated Plasmodium Falciparum

Start: 2022-11-01End: 2022-12-31Updated: 2023-05-16

Combination Momordica Charantia Extract and Primaquine Againts Plasmodium Falciparum Uncomplicated and Plasmodium Vivax Uncomplicated Treatment in Manokwari, West Papua

CompletedNCT06036030

Syamsudin Abdillah,Ph.D, Pharm DInfections, Malaria, Malaria,Falciparum +3

Start: 2019-01-11End: 2019-04-16Updated: 2023-09-13

Efficacy of Dihydroartemisinin for Treating PCOS

CompletedNCT06417099

Shanghai Zhongshan HospitalPolycystic Ovary Syndrome

Start: 2024-05-24End: 2025-03-30Updated: 2025-04-23

Dihydroartemisinin for the Treatment of Polycystic Ovary Syndrome

RecruitingNCT06842524

Shanghai Zhongshan HospitalPolycystic Ovary Syndrome (PCOS)

Start: 2025-04-16End: 2026-12-31Target: 150Updated: 2025-04-20

Phase 4

The Effect of Dihydroartemisinin in PCOS

CompletedNCT05465135

Shanghai Zhongshan HospitalPolycystic Ovary Syndrome

Start: 2022-07-01End: 2023-04-23Updated: 2024-05-17

Related Papers

Dihydroartemisinin for the treatment of polycystic ovary syndrome: study protocol for a multi-centre placebo-controlled randomised clinical trial.

2026-06-19